Danielle Bertoni, MD
Surgical Oncology · Walnut Creek
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 3
- Since medical school
- 19 years
- Graduated 2007
Offices
3 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bertoni’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105375 · Current
Licensed to practise in California · since 2008 · expires 2028-07-31 · Umdnj New Jersey Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Bay Area Surgical Specialists Services, LLC DBA BASS Surgery CenterAmbulatory Surgery Center · Walnut Creek, CA0.21% owner since 2024 · accredited by AAAHCInitial Accreditation2 inspections, 2 with deficiencies · last 2025-06-27
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Surgery - Surgery
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$63,620
Medicare paid this office $63,620 for 126 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Partial removal of breast | 25 | $15,921 | $590 |
| Return visit (30+ min) | 67 | $9,831 | $117 |
| New patient visit (60+ min) | 46 | $8,700 | $189 |
| Long return visit (40+ min) | 39 | $8,430 | $153 |
| Removal of growth of breast identified by x-ray marker, first growth | 12 | $4,797 | $400 |
See all 9 services
| Partial removal of breast | 25 | $15,921 | $590 |
| Return visit (30+ min) | 67 | $9,831 | $117 |
| New patient visit (60+ min) | 46 | $8,700 | $189 |
| Long return visit (40+ min) | 39 | $8,430 | $153 |
| Removal of growth of breast identified by x-ray marker, first growth | 12 | $4,797 | $400 |
| New patient visit (45+ min) | 19 | $2,856 | $150 |
| Short return visit (20+ min) | 15 | $1,568 | $87 |
| Imaging of lymph nodes during surgery | 11 | $1,254 | $114 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 25 | $791 | $29 |
Procedures Medicare counted
| Mastectomy | 31 | More than 87% of doctors who do this |
| Melanoma (skin cancer) excision | 12 | More than 66% of doctors who do this |
| Skin biopsy | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Partial removal of breast | – | – | 18 | 14 | 28 | 27 |
| Imaging of lymph nodes during surgery | – | – | 11 | – | – | 11 |
| Removal of growth of breast identified by x-ray marker, first growth | – | – | – | – | – | 12 |
| Biopsy or removal of deep lymph nodes of underarm | – | – | 12 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
126 Original Medicare patients in 2024. Average age 74 · Health risk score 0.99. At or below the middle of the specialty; the typical surgical oncology clinician is at 1.48.
Conditions among them: Cancer 71% · High blood pressure 63% · Depression 29% · Diabetes 19% · Chronic kidney disease 18% · Coronary heart disease 17% · Atrial fibrillation 12% · COPD 9%.
The office billed $258,857, Medicare allowed $82,840 and paid $63,620; for 350 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 126 | 350 | 74 | 0.99 | $258,857 | $63,620 |
| 2023 | 88 | 278 | 76 | 0.98 | $215,880 | $55,225 |
| 2022 | 63 | 125 | 73 | 0.85 | $81,699 | $20,256 |
| 2021 | 68 | 164 | 69 | 0.96 | $140,473 | $29,037 |
| 2020 | 64 | 113 | 72 | 1.13 | $88,659 | $18,751 |
| 2019 | 67 | 177 | 72 | 1.31 | $163,419 | $28,453 |
| 2018 | 58 | 176 | 72 | 1.30 | $149,735 | $26,784 |
| 2017 | 22 | 31 | 71 | 1.09 | $17,284 | $3,726 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Partial removal of breast | 25 | $15,813 | $565 |
| New patient visit (60+ min) | 60 | $11,451 | $191 |
| Long return visit (40+ min) | 45 | $9,754 | $171 |
| Return visit (30+ min) | 18 | $2,334 | $123 |
| Short return visit (20+ min) | 16 | $1,403 | $83 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 31 | $1,097 | $30 |
2022: 3 services
| Partial removal of breast | 12 | $7,132 | $509 |
| New patient visit (60+ min) | 25 | $5,115 | $205 |
| Short return visit (20+ min) | 16 | $683 | $40 |
2021: 7 services
| Partial removal of breast | 17 | $8,293 | $461 |
| New patient visit (60+ min) | 21 | $2,538 | $121 |
| Biopsy or removal of deep lymph nodes of underarm | 12 | $2,203 | $184 |
| New patient visit (45+ min) | 15 | $1,384 | $92 |
| Imaging of lymph nodes during surgery | 11 | $1,156 | $105 |
| Return visit (30+ min) | 12 | $860 | $66 |
| Short return visit (20+ min) | 17 | $846 | $47 |
2020: 3 services
| New patient visit (60+ min) | 14 | $1,900 | $136 |
| Return visit (30+ min) | 11 | $1,046 | $95 |
| Short return visit (20+ min) | 17 | $871 | $48 |
2019: 5 services
| Return visit (30+ min) | 22 | $2,172 | $91 |
| New patient visit (60+ min) | 12 | $2,109 | $176 |
| Short return visit (20+ min) | 17 | $1,967 | $63 |
| Long return visit (40+ min) | 14 | $1,736 | $116 |
| New patient visit (30+ min) | 12 | $1,085 | $90 |
2018: 6 services
| New patient visit (60+ min) | 17 | $2,996 | $176 |
| Long return visit (40+ min) | 13 | $2,229 | $124 |
| Return visit (30+ min) | 16 | $2,115 | $88 |
| New patient visit (45+ min) | 11 | $1,546 | $141 |
| Short return visit (20+ min) | 16 | $1,436 | $62 |
| New patient visit (30+ min) | 13 | $1,148 | $88 |
Drugs they prescribed that Part D paid
$62
Pharmacies billed $62 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
11 generic and fewer than 11 brand-name prescriptions · $62 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 12 | None | None | None | $62 |
| 2023 | 91 | 34 | 32% (29) | None | $541 |
| 2022 | 36 | 18 | 31% (11) | 0% | $191 |
| 2021 | 110 | 55 | 36% (40) | None | $861 |
| 2020 | 85 | 32 | 38% (32) | 0% | $756 |
| 2019 | 68 | 28 | 24% (16) | None | $588 |
| 2018 | 83 | 29 | 22% (18) | None | $1,043 |
| 2017 | 55 | 28 | 29% (16) | 0% | $1,158 |
| 2016 | 65 | 30 | 35% (23) | 0% | $1,496 |
| 2015 | 66 | 42 | 55% (36) | None | $1,094 |
| 2014 | 37 | 19 | 49% (18) | None | $699 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Ibuprofen | 19 | $130 | $7 |
| Ondansetron Odt | 25 | $78 | $3 |
| Tramadol | 27 | $43 | $2 |
2022: 1 drug
| Ibuprofen | 12 | $54 | $5 |
2021: 3 drugs
| Ibuprofen | 28 | $243 | $9 |
| Oxycodone | 15 | $105 | $7 |
| Tramadol | 13 | $23 | $2 |
2020: 5 drugs
| Raloxifene | 12 | $292 | $24 |
| Ibuprofen | 12 | $99 | $8 |
| Gabapentin | 11 | $97 | $9 |
| Oxycodone-Acetaminophen | 12 | $69 | $6 |
| Tramadol | 14 | $33 | $2 |
2019: 2 drugs
| Ibuprofen | 16 | $114 | $7 |
| Gabapentin | 11 | $68 | $6 |
2018: 1 drug
| Gabapentin | 20 | $146 | $7 |
2017: 3 drugs
| Ibuprofen | 11 | $350 | $32 |
| Hydrocodone-Acetaminophen | 11 | $300 | $27 |
| Ondansetron Odt | 11 | $211 | $19 |
2016: 1 drug
| Ibuprofen | 12 | $252 | $21 |
2015: 1 drug
| Hydrocodone-Acetaminophen | 21 | $348 | $17 |
2014: 1 drug
| Hydrocodone-Acetaminophen | 12 | $132 | $11 |
Money from drug and device companies
$2,748 in 2025
| 2025 | 43 | 110 | None | $2,748 |
| 2024 | 35 | 80 | None | $2,152 |
| 2023 | 12 | 22 | None | $528 |
| 2021 | 1 | 1 | None | $186 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Darzalex | $312 | 13 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $300 | 12 payments
|
| Merck Sharp & Dohme | Keytruda | $222 | 8 payments
|
| Novartis Pharmaceuticals | Kisqali | $213 | 9 payments
|
| Genentech USA | Venclexta | $154 | 6 payments
|
| Jazz Pharmaceuticals | Ziihera | $113 | 3 payments
|
See all 106 published payments
| Legend Biotech USA | Meals · 2025-12-31 | Carvykti | $21 |
| Novartis Pharmaceuticals | Meals · 2025-12-19 | Scemblix | $34 |
| BeOne Medicines USA | Meals · 2025-12-18 | Brukinsa | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-10 | Tagrisso | $18 |
| Invivyd | Meals · 2025-12-10 | Pemgarda | $18 |
| Abbvie | Meals · 2025-12-09 | Venclexta | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-21 | Lynparza | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-21 | Iclusig | $22 |
| Genentech USA | Meals · 2025-11-20 | Phesgo | $24 |
| Janssen Biotech | Meals · 2025-11-19 | Darzalex | $25 |
| Exelixis | Meals · 2025-11-14 | Cabometyx | $45 |
| Genmab U.S. | Meals · 2025-11-14 | Epkinly | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-12 | Calquence | $25 |
| PharmaEssentia USA | Meals · 2025-11-11 | Besremi | $27 |
| Sumitomo Pharma America | Meals · 2025-11-06 | Orgovyx | $19 |
| Janssen Biotech | Meals · 2025-11-03 | Rybrevant | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-30 | Imfinzi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-24 | Tagrisso | $34 |
| Janssen Biotech | Meals · 2025-10-22 | Darzalex | $32 |
| Kyowa Kirin | Meals · 2025-10-22 | Poteligeo | $28 |
| Jazz Pharmaceuticals | Meals · 2025-10-22 | Zepzelca | $40 |
| Merck Sharp & Dohme | Meals · 2025-10-22 | Keytruda | $32 |
| Agios Pharmaceuticals | Meals · 2025-10-20 | Pyrukynd | $25 |
| Servier Pharmaceuticals | Meals · 2025-10-17 | Voranigo | $36 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-15 | None | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-14 | Iclusig | $19 |
| EMD Serono | Meals · 2025-10-08 | None | $27 |
| Genentech USA | Meals · 2025-10-07 | Tecentriq | $32 |
| Pfizer | Meals · 2025-10-01 | Xtandi | $14 |
| Merck Sharp & Dohme | Meals · 2025-09-29 | Keytruda | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-26 | Kisqali | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-26 | Imfinzi | $28 |
| Astellas Pharma US | Meals · 2025-09-25 | Xtandi | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-24 | Iclusig | $18 |
| Genmab U.S. | Meals · 2025-09-19 | Epkinly | $30 |
| GlaxoSmithKline | Meals · 2025-09-17 | Jemperli | $32 |
| Genzyme | Meals · 2025-09-15 | Wayrilz | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-03 | Stivarga | $24 |
| Janssen Biotech | Meals · 2025-09-02 | Darzalex | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-25 | Pluvicto | $28 |
| Karyopharm Therapeutics | Meals · 2025-08-22 | Xpovio | $22 |
| Eisai | Meals · 2025-08-21 | Lenvima | $18 |
| Daiichi Sankyo | Meals · 2025-08-20 | Enhertu | $28 |
| Astellas Pharma US | Meals · 2025-08-19 | Xtandi | $27 |
| Coherus Oncology | Meals · 2025-08-13 | Loqtorzi | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-11 | Tagrisso | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-11 | Imfinzi | $24 |
| Daiichi Sankyo | Meals · 2025-08-05 | Datroway | $18 |
| Caris MPI | Meals · 2025-08-04 | Mi Cancer Seek | $28 |
| Janssen Biotech | Meals · 2025-07-31 | Erleada | $44 |
| Novartis Pharmaceuticals | Meals · 2025-07-09 | Kisqali | $13 |
| Merck Sharp & Dohme | Meals · 2025-07-09 | Keytruda | $18 |
| Astellas Pharma US | Meals · 2025-06-30 | Xtandi | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-25 | Imfinzi | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-24 | Tagrisso | $11 |
| Gilead Sciences | Meals · 2025-06-17 | Trodelvy | $21 |
| Jazz Pharmaceuticals | Meals · 2025-06-13 | Ziihera | $39 |
| Lilly USA | Meals · 2025-06-11 | Verzenio | $33 |
| Novartis Pharmaceuticals | Meals · 2025-06-11 | Kisqali | $22 |
| Recordati Rare Diseases Inc. | Meals · 2025-06-09 | Sylvant | $15 |
| Daiichi Sankyo | Meals · 2025-06-04 | Enhertu | $29 |
| Janssen Biotech | Meals · 2025-06-03 | Rybrevant | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-28 | Iclusig | $18 |
| Stemline Therapeutics | Meals · 2025-05-21 | Orserdu | $56 |
| Janssen Biotech | Meals · 2025-05-20 | Tecvayli | $27 |
| Janssen Biotech | Meals · 2025-05-19 | Tecvayli | $2 |
| Janssen Biotech | Meals · 2025-05-16 | Erleada | $17 |
| Merck Sharp & Dohme | Meals · 2025-05-15 | Keytruda | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-14 | Nubeqa | $30 |
| Novartis Pharmaceuticals | Meals · 2025-05-08 | Pluvicto | $24 |
| Merck Sharp & Dohme | Meals · 2025-05-08 | Keytruda | $30 |
| Novartis Pharmaceuticals | Meals · 2025-05-07 | Kisqali | $13 |
| Merck Sharp & Dohme | Meals · 2025-05-07 | Keytruda | $26 |
| Agios Pharmaceuticals | Meals · 2025-05-06 | Pyrukynd | $20 |
| Hologic Sales and Service | Meals · 2025-05-02 | Trident Specimen Radiography System | $105 |
| Astellas Pharma US | Meals · 2025-05-02 | Xtandi | $22 |
| Janssen Biotech | Meals · 2025-04-25 | Erleada | $19 |
| TerSera Therapeutics | Meals · 2025-04-24 | Xermelo | $21 |
| Genentech USA | Meals · 2025-04-23 | Venclexta | $26 |
| Genzyme | Meals · 2025-04-23 | None | $35 |
| Stemline Therapeutics | Meals · 2025-04-22 | Orserdu | $32 |
| Janssen Biotech | Meals · 2025-04-16 | Darzalex | $25 |
| Servier Pharmaceuticals | Meals · 2025-04-01 | Voranigo | $23 |
| Jazz Pharmaceuticals | Meals · 2025-03-31 | Ziihera | $34 |
| Genentech USA | Meals · 2025-03-25 | Polivy | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-03-24 | Libtayo | $26 |
| Spectrum Pharmaceuticals | Meals · 2025-03-20 | Rolvedon | $19 |
| Fennec Pharmaceuticals | Meals · 2025-03-18 | Fyarro | $22 |
| Novartis Pharmaceuticals | Meals · 2025-03-12 | Kisqali | $29 |
| Novartis Pharmaceuticals | Meals · 2025-03-10 | Lutathera | $20 |
| Merck Sharp & Dohme | Meals · 2025-03-07 | Keytruda | $24 |
| Sobi | Meals · 2025-03-06 | Doptelet | $23 |
| Aveo Pharmaceuticals | Meals · 2025-02-28 | Fotivda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-21 | Calquence | $25 |
| Genentech USA | Meals · 2025-02-21 | Venclexta | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-20 | Enhertu | $30 |
| Janssen Biotech | Meals · 2025-02-19 | Erleada | $16 |
| Janssen Biotech | Meals · 2025-02-11 | Rybrevant | $25 |
| Merck Sharp & Dohme | Meals · 2025-02-06 | Keytruda | $33 |
| Servier Pharmaceuticals | Meals · 2025-02-04 | None | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-29 | Iclusig | $20 |
| Genmab U.S. | Meals · 2025-01-24 | Epkinly | $22 |
| Sobi | Meals · 2025-01-24 | Vonjo | $31 |
| Genentech USA | Meals · 2025-01-15 | Ocrevus Zunovo | $15 |
| Amgen | Meals · 2025-01-13 | Evenity | $23 |
| Myriad Genetic Laboratories | Meals · 2025-01-07 | Precisetumor | $21 |
See earlier years (2024, 2023, 2021)
2024: $2,152
| AstraZeneca Pharmaceuticals LP | Imfinzi | $291 | 12 payments
|
| Merck Sharp & Dohme | Keytruda | $235 | 9 payments
|
| Janssen Biotech | Carvykti | $192 | 8 payments
|
| Silk Road Medical | Enroute Transcarotid Stent | $172 | 2 payments
|
| Endomagnetics | Magseed | $136 | 2 payments
|
| Novartis Pharmaceuticals | Scemblix | $105 | 4 payments
|
| Medtronic | Venaseal | $82 | 1 payment
|
| Abbvie | Epkinly | $63 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $50 | 2 payments
|
| Telix Pharmaceuticals | Illuccix | $49 | 2 payments
|
| Lilly USA | Verzenio | $46 | 2 payments
|
| Myriad Genetic Laboratories | Precisetumor | $45 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $45 | 2 payments
|
| Eisai | Leqembi | $44 | 2 payments
|
| Gilead Sciences | None | $44 | 2 payments
|
| Recordati Rare Diseases Inc. | Sylvant | $42 | 2 payments
|
| Agios Pharmaceuticals | None | $38 | 1 payment
|
| Stemline Therapeutics | Orserdu | $37 | 1 payment
|
| Pfizer | Oxbryta | $35 | 1 payment
|
| Genentech | Columvi | $33 | 1 payment
|
| Genmab U.S. | Epkinly | $33 | 1 payment
|
| Coherus Biosciences | Loqtorzi | $31 | 1 payment
|
| Exelixis | Cabometyx | $30 | 1 payment
|
| Stryker | Eikon | $29 | 2 payments
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $29 | 1 payment
|
| Mirati Therapeutics | Krazati | $26 | 1 payment
|
| ADC Therapeutics America | None | $26 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $24 | 1 payment
|
| Taiho Oncology | Lonsurf | $23 | 1 payment
|
| Argenx US | Vyvgart Hytrulo | $22 | 1 payment
|
| Boston Scientific | Spaceoar Vue System - 10ml | $22 | 1 payment
|
| Sobi | Synagis | $21 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $20 | 1 payment
|
| Astellas Pharma US | Padcev | $18 | 1 payment
|
| Genentech USA | Ocrevus | $17 | 1 payment
|
2023: $528
| Telix Pharmaceuticals | Illuccix | $116 | 5 payments
|
| Myriad Genetic Laboratories | Myrisk | $79 | 3 payments
|
| Molli Surgical (us) | None | $73 | 3 payments
|
| Janssen Biotech | Erleada | $48 | 2 payments
|
| Hologic Sales and Service | Biozorb | $38 | 2 payments
|
| Amgen | Evenity | $29 | 1 payment
|
| KUB Technologies | Mozart | $28 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $28 | 1 payment
|
| Boston Scientific | Spaceoar Vue System - 10ml | $24 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $23 | 1 payment
|
| Genentech USA | Ocrevus | $22 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $19 | 1 payment
|
2021: $186
| Endomagnetics | Magseed | $186 | 1 payment
|
Professional record
- NPI
- 1780843185
- Licence
- CA A105375, CT 57058, OR MD199112California A105375: Current · expires 2028-07-31
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Surgery (208600000X); Surgical oncology (2086X0206X)
- Mailing address
- 575 Lennon Ln, Walnut Creek, CA, 94598
- NPI first listed
- 2008-06-02
- NPI last updated
- 2026-09-02
- NPI record certified
- 2026-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 6600 Lone Tree Way, Brentwood, CA, 94513